SCNLF (Scancell Holdings) Interest Expense: $-2.52 Mil (TTM As of Oct. 2025)

What is Scancell Holdings Interest Expense?

Scancell Holdings SCNLF 20 Interest Expense is $-2.52 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scancell Holdings's interest expense for the six months ended in Oct. 2025 was $ -1.30 Mil. Its interest expense for the trailing twelve months (TTM) ended in Oct. 2025 was $-2.52 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scancell Holdings's Operating Income for the six months ended in Oct. 2025 was $ -11.87 Mil. Scancell Holdings's Interest Expense for the six months ended in Oct. 2025 was $ -1.30 Mil. Scancell Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scancell Holdings (OTCPK:SCNLF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scancell Holdings's Interest Expense for the six months ended in Oct. 2025 was $-1.30 Mil. Its Operating Income for the six months ended in Oct. 2025 was $-11.87 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Oct. 2025 was $0.00 Mil.

Scancell Holdings's Interest Coverage for the quarter that ended in Oct. 2025 is calculated as

Scancell Holdings did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Scancell Holdings Interest Expense Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Interest Expense can be seen below:

Scancell Holdings Interest Expense Chart

Scancell Holdings Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

Interest Expense

Get a 7-Day Free Trial

-2.29

-2.30

-1.51

-1.36

-2.26

Scancell Holdings Semi-Annual Data
	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23	Apr24	Oct24	Apr25	Oct25
Interest Expense	Get a 7-Day Free Trial															-0.60	-0.75	-1.03	-1.21	-1.30

20GF Score

Scancell Holdings PLC SCNLF

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Scancell Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.52 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-2.52 Mil mean?

Scancell Holdings (SCNLF) has a Interest Expense of $-2.52 Mil as of Oct. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Scancell Holdings and its competitors.

Is Scancell Holdings' Interest Expense too high?

Scancell Holdings' current Interest Expense is $-2.52 Mil. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.

How does Scancell Holdings' Interest Expense compare to VRTX and REGN?

Scancell Holdings' Interest Expense of $-2.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Interest Expense is $-2.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Scancell Holdings stock overvalued right now?

Scancell Holdings (SCNLF) has a current Interest Expense of $-2.52 Mil. The current Interest Expense is $-2.52 Mil. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Interest Expense is $-2.52 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:BVXP LSE:FARN LSE:4BB LSE:PRTC LSE:HEMO LSE:POLB LSE:IBT LSE:COIL LSE:SBTX LSE:SAR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SCLP:UK SCP:Germany

Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website https://www.scancell.co.uk

Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.

20GF Score

Get the complete analysis for SCNLF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28

Price

View SCNLF Analysis

See Interest Expense data for all stocks →